Research & Development

Pharma R&D partnerships are on the rise: report

Pharma R&D partnerships are on the rise: report

By

This is likely due, in part, to the increasingly complex nature of new specialty drugs.

In Merck video, woman says a cure is the greatest invention

In Merck video, woman says a cure is the greatest invention

By

The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.

Large teaching hospitals more prone to breaches

Large teaching hospitals more prone to breaches

By

These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.

Five things for pharma marketers to know: Friday, March 24, 2017

Five things for pharma marketers to know: Friday, March 24, 2017

By

Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

By

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Five things for pharma marketers to know: Wednesday, March 8, 2017

Five things for pharma marketers to know: Wednesday, March 8, 2017

By

Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs

When It Comes to the FDA, Does It All Come Down to Money?

When It Comes to the FDA, Does It All Come Down to Money?

In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?

Is the Trump Administration the Cure the FDA Needs?

Is the Trump Administration the Cure the FDA Needs?

Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

By By

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena

Five things for pharma marketers to know: Monday, February 6, 2017

Five things for pharma marketers to know: Monday, February 6, 2017

By

Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year

Five things for pharma marketers to know: Monday, January 9, 2017

Five things for pharma marketers to know: Monday, January 9, 2017

By

Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal

QuintilesIMS taps Staub as head of R&D solutions

QuintilesIMS taps Staub as head of R&D solutions

By

The merger of Quintiles and IMS Health closed in October.

Sermo and Everyday Health partner in advertising-research deal

Sermo and Everyday Health partner in advertising-research deal

By

The partnership allows Sermo to expand the reach of its research initiatives and Everyday Health to scale its targeted advertising on the social platform.

Five things for pharma marketers to know: Thursday, August 11, 2016

Five things for pharma marketers to know: Thursday, August 11, 2016

By

Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana

Pharma companies turn to wearables to improve R&D

Pharma companies turn to wearables to improve R&D

By

Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.

How Watson for Oncology is advancing cancer care

How Watson for Oncology is advancing cancer care

By

IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.

Precision for Medicine acquires ACT Oncology

Precision for Medicine acquires ACT Oncology

By

The scientific services company expands its portfolio to include expertise in oncology clinical studies.

Startup unveils tools to improve trial reproducibility

Startup unveils tools to improve trial reproducibility

By

The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.

Five things for pharma marketers to know: Wednesday, January 13, 2016

Five things for pharma marketers to know: Wednesday, January 13, 2016

By

Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup

Five things for pharma marketers to know: Friday, November 20

Five things for pharma marketers to know: Friday, November 20

By

AstraZeneca and Sanofi to share compounds in rare agreement; FDA advisory committee votes against bladder cancer drug; Allergan may buyer in Pfizer deal

Pharma CEOs defend R&D model to investors

Pharma CEOs defend R&D model to investors

By

Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.

Valeant's controversial model undergoing changes, says CEO

Valeant's controversial model undergoing changes, says CEO

By

The drugmaker, which recently drew scrutiny from lawmakers, is planning to change some of its most contentious business practices. Experts say Valeant also needs to educate lawmakers and the public about the value of its medicines.

Five things for pharma marketers to know: Tuesday, August 18

Five things for pharma marketers to know: Tuesday, August 18

By

Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children

Drugs that turn cancer into a chronic disease need new marketing strategies: report

Drugs that turn cancer into a chronic disease need new marketing strategies: report

By

Findings of a new report suggest ways pharma should rethink its commercial and R&D decisions in light of improved survival rates associated with some cancers.

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Five things for pharma marketers to know: Monday, July 27

Five things for pharma marketers to know: Monday, July 27

By

Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend

Five things for pharma marketers to know: Wednesday, July 22

Five things for pharma marketers to know: Wednesday, July 22

By

Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed

Five things for pharma marketers to know: Wednesday, July 15

Five things for pharma marketers to know: Wednesday, July 15

By

Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands

More than 400 drugs in development for neurological disorders

PhRMA and the Epilepsy Foundation said 50-million Americans are affected by disorders such as Alzheimer's disease and multiple sclerosis.

Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

By

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Opinion

Newsletters

MM&M's T40

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.